Since the beginning of the COVID-19 pandemic, a number of treatments and techniques have been put in place to supposedly combat the new coronavirus (SARS-CoV-2). Almost a year later, researchers can already distinguish what has practical effects against this infectious agent (or not). In this scenario, the National Health Surveillance Agency (Anvisa) published a technical note on the ineffectiveness of the use of ozone against this virus.
“With the advent of the pandemic caused by the new coronavirus (Sars-CoV-2), many equipment and devices have claimed efficiency in disinfecting surfaces, and even people, without adequate scientific evidence”, the agency points out, in a note. Among these solutions, there would also be the use of ozone.
According to the document issued by the agency, “Anvisa has not been presented with scientific evidence on the disinfectant effectiveness of ozone against Sars-CoV-2”. In other words, the use of the technique is not effective against the COVID-19 virus. The agency’s statement was made based on a review of data from available national and international studies.
When is ozone use valid?
Although ozone has a disinfectant action in water for human consumption and is used for this purpose, mainly in Europe, Anvisa states that “Ozone is a gas that can be used as a disinfectant. However, for it to be effective in destroying bacteria harmful [ou outros agentes infecciosos], it must be present in a concentration above the levels considered safe for human beings “. Given these conditions, the agency emphasizes that the use of ozone has the potential to cause acute and chronic damage to humans, characterized by skin lesions, in the pathways respiratory and eye conditions, and allergic reactions.
According to the legal and regulatory frameworks in force, equipment or structures that use ozone to disinfect public environments and surfaces in general are not subject to regulation by Anvisa. However, tests to prove the efficacy and safety of the substance produced by this equipment must be carried out and maintained by the companies, for eventual inspection. It is also necessary to have authorization for clinical studies, aiming at treatments of COVID-19, in humans.
However, Anvisa points out that this information can be changed at any time, considering possible updates on the subject, as long as there is new evidence and clinical studies proving the effectiveness of the treatment.
To read the full technical note 108/2020, issued by Anvisa, click here.
Did you like this article?
Subscribe your email to Canaltech to receive daily updates with the latest news from the world of technology.